PMI to Launch VEEV Vape Brand in Germany to Compete with Vuse

JTI by 2FIRSTS, edited by Sophia
Apr.09.2024
PMI to Launch VEEV Vape Brand in Germany to Compete with Vuse
PMI launches VEEV vape brand in Germany, competing with Vuse from China and BAT, targeting tobacco users.

According to the German media Nouvelles, Philip Morris International (PMI) has decided to launch its vape brand VEEV in Germany, thereby competing with major Chinese manufacturers as well as the rival product Vuse from British American Tobacco (BAT). Although PMI had already included e-cigarettes in its product line several years ago and sold them in other countries such as Poland, the Czech Republic, and Greece, it had never sold e-cigarettes in Germany.

 

PMI to Launch VEEV Vape Brand in Germany to Compete with Vuse
Disposable product VEEV NOW | Image source: PMI

 

PMI to Launch VEEV Vape Brand in Germany to Compete with Vuse
Pod-system product VEEV ONE | Image source: PMi

 

PMI's Chief Spokesperson, Torsten Albig, stated in a media interview, "We have made extensive and intensive efforts at the government level to ban the sale of disposable e-cigarettes, but to no avail. Therefore, we have decided to enter this market as well."

 

Among teenagers and young people, disposable e-cigarettes are particularly popular. However, the German Federal Ministry of Food and Agriculture appears to be considering banning the use of mint as an ingredient in e-cigarettes in order to reduce the possibility of e-cigarettes gaining market share. However, policymakers in other European countries have responded more uniformly to this issue. For example, countries like France and Belgium will ban the sale of disposable e-cigarettes starting next year.

 

PMI is planning to launch a rechargeable e-cigarette while also selling disposable products. "But this should only be a test product," Albig explained.

 

PMI's current sales policy is to offer a free VEEV charging device with the purchase of three disposable e-cigarettes. This promotion is taking place at participating retailers and the company's IQOS stores. Altria announced that VEEV will be introduced in stores located in major cities that previously only sold heated tobacco products.

 

However, he also admitted that the introduction of e-cigarettes is not just a response to policy loopholes.

 

He pointed out:

 

If we want to achieve our global goals as a group and have over two-thirds of our net revenue contributed by tobacco alternatives by 2030, we cannot afford to leave the German market.

 

In this country, PMI and its IQOS heated tobacco products only occupy a market share of 6%, slightly higher in major cities at just over 10%. Meanwhile, their Marlboro cigarettes hold a 25% market share.

 

PMI hopes to attract smokers with the e-cigarette VEEV and provide competitive pricing: the disposable version will be sold for 7.90 euros, while two refill pods for the reusable system will be priced at 8.90 euros.

 

Although competitors' disposable e-cigarettes are generally priced at ten euros or higher, PMI has decided to challenge their position. Alberg remains calm about the ban on using mint or flavorings in e-cigarettes. He said, "If that's how it is, then so be it. Our products are not meant to attract young people, but to satisfy cigarette smokers who are already accustomed to the taste of tobacco.

 

The World Health Organization has clearly stated that alternative tobacco products are not healthier than traditional tobacco. At the same time, scientists who receive funding from the tobacco industry for research are often suspected of lobbying for the tobacco industry.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

FDA Grants MRTP Orders for 20 ZYN Nicotine Pouches
FDA Grants MRTP Orders for 20 ZYN Nicotine Pouches
The U.S. Food and Drug Administration (FDA) has issued modified risk granted orders to Swedish Match USA for 20 ZYN nicotine pouch products, allowing the already-authorized products to be marketed with a specific claim that using ZYN instead of cigarettes lowers the risk of mouth cancer, heart disease, lung cancer, stroke, emphysema and chronic bronchitis.
Jul.01
Japan’s Heated Tobacco Tax Changes Reshape Consumer Choices, Survey Reveals Impact of Price and Income
Japan’s Heated Tobacco Tax Changes Reshape Consumer Choices, Survey Reveals Impact of Price and Income
A consumer survey by Japanese heated tobacco information platform RELAZO found that rising tobacco prices and planned heated tobacco tax changes may influence smoking decisions among Japanese consumers. The survey covered 49,879 men and women aged 20 to 69 nationwide. It found that around 40% of respondents cumulatively indicated they may consider quitting when a pack reaches ¥600 (approximately US$4.1), while nearly 90% expressed potential quitting intentions at a ¥1,000 (approximately US$6.8) price level. The survey also found significant differences by income level, with lower-income respondents showing greater sensitivity to price increases.
Jul.24
Special Report|South Korean Lawmaker Queries China Tobacco Regulator Over Synthetic Nicotine as Export-Rule Gaps Emerge
Special Report|South Korean Lawmaker Queries China Tobacco Regulator Over Synthetic Nicotine as Export-Rule Gaps Emerge
A South Korean lawmaker has asked China’s tobacco regulator to clarify rules for e-cigarettes containing synthetic nicotine amid questions over product declarations and possible tax losses. The dispute exposes gaps between Chinese export requirements and destination-market rules, while underscoring the global impact of China’s licensing and traceability policies.
Jul.10
Ohio Supreme Court Weighs Whether State Consumer Law Can Restrict Flavored Vape Sales
Ohio Supreme Court Weighs Whether State Consumer Law Can Restrict Flavored Vape Sales
The Ohio Supreme Court is hearing a case involving flavored vape sales and whether state authorities can use consumer protection laws to take action against retailers selling unauthorized vape products. Ohio officials argue that selling unauthorized flavored vapes may constitute consumer deception, while retailers argue that tobacco product regulation falls under federal Food and Drug Administration (FDA) authority and that states cannot impose additional restrictions through consumer laws. The case could affect the scope of state-level vape regulation across the United States.
Aug.06
UK Vape Tax Countdown: Retailer Vape HQ Estimates 100ml E-liquid Prices Could Rise From £12.99 to £39.39, While Pod Kits Increase Less Than 10%
UK Vape Tax Countdown: Retailer Vape HQ Estimates 100ml E-liquid Prices Could Rise From £12.99 to £39.39, While Pod Kits Increase Less Than 10%
The UK’s Vaping Products Duty (VPD), scheduled to take effect in October 2026, is prompting retailers to assess how different vape categories may be affected. UK retailer Vape HQ has estimated potential price changes under the new volume-based tax system, showing that 100ml shortfill e-liquids could see prices rise from around £12.99 to £39.39, a 203% increase, while 2ml prefilled pod vape kits could rise from £5.99 to £6.52, an increase of about 9%. The estimates highlight how a volume-based tax structure creates uneven cost impacts across product categories.
Aug.19
JAMA Issues First U.S. Clinical Guidance on Vaping for Smoking Cessation, Urging Complete Switch From Cigarettes
JAMA Issues First U.S. Clinical Guidance on Vaping for Smoking Cessation, Urging Complete Switch From Cigarettes
JAMA has published a Special Communication offering systematic recommendations for U.S.-based clinicians on the use of nicotine e-cigarettes in adult smoking cessation. Developed by the Harm Reduction Workgroup of the Society for Research on Nicotine and Tobacco’s Treatment Research Network, the paper recommends including e-cigarettes alongside FDA-approved cessation medications in risk-benefit discussions. It cites high-certainty evidence that nicotine e-cigarettes achieve higher quit rates than nicotine replacement therapy and evidence suggesting efficacy comparable to highly effective medications such as varenicline and cytisine. For adults who choose vaping to quit, the authors recommend FDA-authorized products, sufficient nicotine delivery and a rapid, complete transition away from cigarettes rather than prolonged dual use.
Aug.13